Buy Depo Provera® suspension 150 mg/ml 3.3 ml vials 1 pc.

Depo Provera® [Medroxyprogesterone]

Brand Pfizer

In stock 759 Items

Available since: 2019-09-19

Dosage form

suspension

Brand & Manufacturer

Package Size

150 mg/ml 1 ml vials 1 pc.
150 mg/ml 3.3 ml vials 1 pc.

$24.69

Quantity

All payments are SSL encrypted
Full Refund if you haven't received your order
International shipping to the USA, UK and Europe

Clinical Pharmacology

Depo Provera® is an anticancer drug, the gestagen is a depot form. Does not possess androgenic and estrogenic activity. Depo-Provera inhibits the secretion of gonadotropic hormones (especially LH). In small doses, inhibits ovulation. It has an inhibitory effect on the changes needed to prepare the endometrium for implantation of a fertilized egg and increases the viscosity of the mucus of the cervix. Depo-Provera in higher doses has an antitumor effect in hormone-sensitive malignant tumors. This effect is apparently due to the action on steroid hormone receptors and on the pituitary-gonadal system.

Indications

Additional and palliative treatment for recurrent and metastatic endometrial cancer or kidney cancer; palliative treatment for hormone-dependent forms of recurrent breast cancer in postmenopausal women.

Composition

1 ml of suspension contains:

Active substance: methylprednisolone acetate 150 mg;

Excipients: polyethylene glycol 3350; polysorbate 80; sodium chloride; methyl paraben; propyl paraben; water for injections.

No customer reviews for the moment.

Write your review

Dosage and Administration

Set individually, depending on the evidence, the stage of the disease, the treatment regimen.

Withendometrial cancer and kidney cancer the initial dose is 400-1000 mg per week IM. If within a few weeks or months there has been an improvement and stabilization of the process has been achieved, then maintenance therapy is prescribed at a dose of 400 mg per month.

In breast cancer the drug is administered i / m at the initial dose of 500 mg per day for 28 days. Then use maintenance doses - 500 mg 2 times a week. Treatment continues until signs of disease progression.

Immediately before use, the vial should be shaken well, so that the injected drug takes on the appearance of a homogeneous suspension.

Adverse reactions

Allergic reactions:anaphylaxis and anaphylactoid reactions, urticaria.

From the blood coagulation system: thromboembolism, thrombophlebitis.

From the side of the central nervous system: increased nervous irritability, insomnia, drowsiness, fatigue, depression, dizziness, headache.

Dermatological reactions: itching, rash, acne, hirsutism and alopecia.

From the reproductive system: dysfunctional uterine bleeding, bloody discharge from the genital tract, amenorrhea, decreased libido or anorgasmia, vaginitis, leucorrhea, hot flashes, lower abdominal pain, breast tenderness, galactorrhea.

From the digestive system: pain or discomfort in the stomach, nausea, flatulence.

From the musculoskeletal system: cramps gastrocnemius muscles, pain in the back and joints.

Other: asthenia, hyperthermia, change in body weight and moon face.

Hypersensitivity to the components of the drug, pregnancy, lactation.

Special instructions

It is necessary to strictly observe the compliance of the used dosage form of the drug with indications for use.

Medroxyprogesterone should be used with extreme caution in patients with thrombophlebitis, thromboembolic complications, severe impaired liver function, and hypercalcemia.

Before using medroxyprogesterone for the treatment of gynecological diseases and contraception it is necessary to exclude the presence in the patient of a tumor of the genital organs or mammary glands.

When conducting histopathological studies of certain organs and tissues, it is necessary to warn the histologist about the previous treatment with progestogens. Against the background of medroxyprogesterone, changes in the results of the following studies are possible: determination of the level of gonadotropins; determining the level of progesterone, cortisol, testosterone (in men), estrogen (in women) in the blood plasma; determination of the level of pregnandiol in the urine; carrying out tests with sugar loading; a test with a metapiron.